Literature DB >> 18988302

Association of p53 codon 72 polymorphism with liver metastases of colorectal cancers positive for p53 overexpression.

Zhong-Zheng Zhu1, Bing Liu, Ai-Zhong Wang, Hang-Ruo Jia, Xia-Xiang Jin, Xiang-Lei He, Li-Fang Hou, Guan-Shan Zhu.   

Abstract

OBJECTIVE: To evaluate the association between p53 codon 72 polymorphism (R72P) and the risk of colorectal liver metastases.
METHODS: The p53 R72P genotype was identified by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) method in 78 consecutive colorectal cancer patients with liver metastases and 214 age- and sex-matched cases with nonmetastatic colorectal cancer.
RESULTS: The R allele of the p53 R72P polymorphism was more frequently found in metastatic cases than in nonmetastatic cases (P=0.075). Carriers of the 72R allele had a 2.25-fold (95% CI (confidence interval)=1.05 to approximately 4.83) increased risk of liver metastases. On the stratification analysis, 72R-carrying genotype conferred a 3.46-fold (95% CI=1.02 to approximately 11.72) and a 1.05-fold (95% CI=0.36 to approximately 3.08) increased risk of liver metastases for p53 overexpression-positive and negative colorectal cancers, respectively.
CONCLUSION: These results demonstrate for the first time that the 72R allele of the p53 polymorphism has an increased risk for liver metastases in colorectal cancers positive for p53 overexpression.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18988302      PMCID: PMC2579946          DOI: 10.1631/jzus.B0820100

Source DB:  PubMed          Journal:  J Zhejiang Univ Sci B        ISSN: 1673-1581            Impact factor:   3.066


  37 in total

1.  Histopathologic characteristics of colorectal cancer with liver metastasis.

Authors:  Y Adachi; M Inomata; K Kakisako; K Sato; N Shiraishi; S Kitano
Journal:  Dis Colon Rectum       Date:  1999-08       Impact factor: 4.585

2.  Two polymorphic variants of wild-type p53 differ biochemically and biologically.

Authors:  M Thomas; A Kalita; S Labrecque; D Pim; L Banks; G Matlashewski
Journal:  Mol Cell Biol       Date:  1999-02       Impact factor: 4.272

3.  p53 polymorphism and risk of cervical cancer.

Authors:  S Lanham; I Campbell; P Watt; R Gornall
Journal:  Lancet       Date:  1998-11-14       Impact factor: 79.321

4.  Correlation of intratumoral microvessel density and p53 protein overexpression in human colorectal adenocarcinoma.

Authors:  P B Vermeulen; L Roland; V Mertens; E Van Marck; E A De Bruijn; A T Van Oosterom; L Y Dirix
Journal:  Microvasc Res       Date:  1996-03       Impact factor: 3.514

5.  Flow cytometric examination of p53 protein in primary tumors and metastases to the liver and lymph nodes of colorectal cancer.

Authors:  O Kimura; K Sugamura; T Kijima; M Makino; H Shirai; S Tatebe; H Ito; N Kaibara
Journal:  Dis Colon Rectum       Date:  1996-12       Impact factor: 4.585

6.  Combined analysis of p53 and vascular endothelial growth factor expression in colorectal carcinoma for determination of tumor vascularity and liver metastasis.

Authors:  S M Kang; K Maeda; N Onoda; Y S Chung; B Nakata; Y Nishiguchi; M Sowa
Journal:  Int J Cancer       Date:  1997-10-21       Impact factor: 7.396

7.  p53 protein accumulation and p53 gene mutation in esophageal carcinoma. A molecular and immunohistochemical study with clinicopathologic correlations.

Authors:  G Coggi; S Bosari; M Roncalli; D Graziani; P Bossi; G Viale; R Buffa; S Ferrero; M Piazza; S Blandamura; A Segalin; L Bonavina; A Peracchia
Journal:  Cancer       Date:  1997-02-01       Impact factor: 6.860

8.  Increased incidence of p53 mutations is associated with hepatic metastasis in colorectal neoplastic progression.

Authors:  W V Kastrinakis; N Ramchurren; K M Rieger; D T Hess; M Loda; G Steele; I C Summerhayes
Journal:  Oncogene       Date:  1995-08-17       Impact factor: 9.867

Review 9.  Colorectal liver metastases.

Authors:  D Burke; T G Allen-Mersh
Journal:  Postgrad Med J       Date:  1996-08       Impact factor: 2.401

10.  Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1.

Authors:  K M Dameron; O V Volpert; M A Tainsky; N Bouck
Journal:  Science       Date:  1994-09-09       Impact factor: 47.728

View more
  4 in total

1.  p53 codon 72 polymorphism and liver cancer susceptibility: a meta-analysis of epidemiologic studies.

Authors:  Xi Chen; Fei Liu; Bo Li; Yong-Gang Wei; Lv-Nan Yan; Tian-Fu Wen
Journal:  World J Gastroenterol       Date:  2011-03-07       Impact factor: 5.742

2.  TP53 codon 72 polymorphism and colorectal cancer susceptibility: a meta-analysis.

Authors:  Jing-Jun Wang; Yuan Zheng; Liang Sun; Li Wang; Peng-Bo Yu; Jian-Hua Dong; Lei Zhang; Jing Xu; Wei Shi; Yu-Chun Ren
Journal:  Mol Biol Rep       Date:  2010-12-08       Impact factor: 2.316

3.  SPARCL1, Shp2, MSH2, E-cadherin, p53, ADCY-2 and MAPK are prognosis-related in colorectal cancer.

Authors:  Shu-Jing Yu; Jie-Kai Yu; Wei-Ting Ge; Han-Guang Hu; Ying Yuan; Shu Zheng
Journal:  World J Gastroenterol       Date:  2011-04-21       Impact factor: 5.742

4.  Association of p53 rs1042522, MDM2 rs2279744, and p21 rs1801270 polymorphisms with retinoblastoma risk and invasion in a Chinese population.

Authors:  Rongxin Chen; Shu Liu; Huijing Ye; Jiali Li; Yi Du; Lingyan Chen; Xiaoman Liu; Yungang Ding; Qian Li; Yuxiang Mao; Siming Ai; Ping Zhang; Wenfang Ma; Huasheng Yang
Journal:  Sci Rep       Date:  2015-08-20       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.